Skip to main content

Table 1 Baseline characteristics in 278 premenopausal patients according to LHR insLQ and GnRH 16Ser carriership

From: GnRH and LHRgene variants predict adverse outcome in premenopausal breast cancer patients

   LHR insLQ   GnRH 16Ser  
Feature Number (percent) Non-carriers (percent) Carriers (percent)a P valuea Non-carriers (percent) Carriers (percent) P valuea
Breast cancer cases 278 (100) 147 (53) 131 (47)   157 (56) 121 (44)  
Age in years     0.18    0.56
   <35 19 (7) 12 7   9 10  
   35–39 35 (12) 13 22   17 18  
   40–49 167 (60) 93 74   99 68  
   50–59 57 (21) 29 28   32 25  
Node status     0.78    0.001 b
   Negative 134 (48) 72 62   89 45  
   Positive 144 (52) 75 69   68 76  
Histological grade c     0.04    0.15
   Well/mod 66 (24) 44 22   41 25  
   unknown 59 (21) 28 31   27 32  
   Poor 153 (55) 75 78   89 64  
Tumor size d     0.58    0.30
   ≤2 cm 113 (41) 62 51   68 45  
   >2 cm 165 (59) 85 80   89 76  
Estrogen receptor status c,e     0.095    0.29
   Negative 78 (28) 35 43   48 30  
   Positive 200 (72) 112 88   109 91  
Progesterone receptor status c,e     0.15    0.54f
   Negative 70 (25) 32 38   42 28  
   Positive 199 (72) 111 88   111 88  
HER2 amplified c     0.68    0.85
   Yes 55 (20) 28 27   30 25  
   No 202 (73) 106 96   114 88  
Adjuvant therapy     0.54    0.09
   No 158 (57) 88 70   96 62  
   Hormonal 4 (1) 1 3   1 3  
   Chemotherapy 110 (40) 55 55   55 55  
   Combined 6 (2) 3 3   5 1  
  1. aχ2 test. bAlso, when stratified per 'genotype', P = 0.003. cNumbers in cells may not add up due to incomplete information on histological grade and/or receptor status. dTumors of unknown size (n = 10) are included as tumor size >2 cm. eThe cutoff value used was 10 fmol/mg protein. fSignificant when stratified per 'genotype', P = 0.02. Entries in bold represent significant outcomes.